InMed Launches Study on Cannabis-Based COPD Therapy


InMed Pharmaceuticals is expanding its product line by initiating studies on a potential treatment for chronic obstructive pulmonary disease (COPD). The clinical stage company specializes in the development of therapeutic options based on cannabis, and will launch a new program designed to discover and assess cannabinoid compounds able to treat COPD.

InMed announced that its new program focused on finding cannabis-based treatments for COPD has already initiated its first drug discovery efforts and preclinical tests in partnership with investigators from the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia in Vancouver, Canada.

“We’re excited to explore avenues to further expand InMed’s pipeline with the addition of new program targeting COPD, the third leading cause of death in the United States,” said InMed’s president and CEO Craig Schneider. COPD is a chronic pulmonary disease that affects more than 50 million people worldwide and progressively degrades the ability to breathe, increasing mucus production, cough and chest tightness.

More: http://lungdiseasenews.com/2015/06/05/inmed-launches-study-cannabis-based-copd-therapy/

Print Friendly, PDF & Email